Giuseppe Orlando to Disease Progression
This is a "connection" page, showing publications Giuseppe Orlando has written about Disease Progression.
Connection Strength
0.189
-
Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol. 2008 Nov; 20(1-2):43-7.
Score: 0.070
-
Iorio J, Orlando G, Diefenbach C, Gaughan JP, Samdani AF, Pahys JM, Betz RR, Cahill PJ. Serial Casting for Infantile Idiopathic Scoliosis: Radiographic Outcomes and Factors Associated With Response to Treatment. J Pediatr Orthop. 2017 Jul/Aug; 37(5):311-316.
Score: 0.032
-
Stratta RJ, Rogers J, Farney AC, Orlando G, El-Hennawy H, Gautreaux MD, Reeves-Daniel A, Palanisamy A, Iskandar SS, Bodner JK. Pancreas transplantation in C-peptide positive patients: does "type" of diabetes really matter? J Am Coll Surg. 2015 Apr; 220(4):716-27.
Score: 0.027
-
Manzia TM, Angelico R, Baiocchi L, Toti L, Ciano P, Palmieri G, Angelico M, Orlando G, Tisone G. The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up. Transpl Int. 2013 Mar; 26(3):259-66.
Score: 0.024
-
Manzia TM, Angelico R, Toti L, Bellini MI, Sforza D, Palmieri G, Orlando G, Tariciotti L, Angelico M, Tisone G. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int. 2011 May; 24(5):461-8.
Score: 0.021
-
Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, Lionetti R, Anselmo A, Toti L, Angelico M. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol. 2006 Apr; 44(4):702-9.
Score: 0.015